Sign In
News Digest /
Ticker: VKTX
Ticker: VKTX
02:57am, Wednesday, Aug 20, 2025
Viking Therapeutics (VKTX) plunged ~37% after Phase 2 VENTURE showed VK2735 met its primary endpoint-up to 12.2% weight loss at 13 weeks-but a 28% discontinuation rate and GI side effects spurred adoption worries; Eli Lilly (LLY) edged up.
06:02pm, Wednesday, Jul 23, 2025
Viking Therapeutics, Inc. (NASDAQ: VKTX) is currently navigating significant developments in its operations and financial performance, as illustrated by its latest quarterly filing. Here's a synthesis of the company's recent activities and its financial status based on the second quarter of 2025....
05:02pm, Thursday, Apr 24, 2025
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. Here are key points regarding the company’s recent financial performance and operational developments as reflected in their late...
05:54am, Monday, Aug 26, 2024
Viking Therapeutics (VKTX) has tripled in value this year, with analysts projecting a price target of $113.55. The company's success hinges on its phase 3 trial for VK2735, a promising appetite-suppressing drug. Caution is advised due to recent losses.
03:37am, Friday, Jul 26, 2024
Eli Lilly & Co. (NYSE: LLY) faces a $120 billion market cap loss as rivals advance in the obesity drug space. With a stock drop of 14% in eight days, analysts warn of looming challenges despite a positive year-to-date. The upcoming earnings report could be pivotal.
08:07am, Friday, Mar 22, 2024
Viking Therapeutics emerges as a significant player in the weight loss drug market, with its latest data suggesting a "best-in-class" potential.